Stock Traders Purchase High Volume of Call Options on Veru (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERU) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 8,511 call options on the stock. This is an increase of approximately 500% compared to the average daily volume of 1,418 call options.

Veru Stock Down 4.6 %

Shares of NASDAQ:VERU opened at $1.04 on Thursday. The company has a market cap of $152.24 million, a PE ratio of -3.71 and a beta of -0.53. Veru has a fifty-two week low of $0.36 and a fifty-two week high of $1.92. The firm has a 50-day simple moving average of $0.71 and a 200 day simple moving average of $0.80.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%. As a group, research analysts forecast that Veru will post -0.26 EPS for the current fiscal year.

Institutional Trading of Veru

A number of hedge funds and other institutional investors have recently made changes to their positions in VERU. SG Americas Securities LLC increased its position in shares of Veru by 132.4% during the 4th quarter. SG Americas Securities LLC now owns 153,656 shares of the company’s stock valued at $100,000 after purchasing an additional 87,528 shares during the period. 180 Wealth Advisors LLC raised its holdings in Veru by 41.0% during the 4th quarter. 180 Wealth Advisors LLC now owns 293,350 shares of the company’s stock worth $191,000 after buying an additional 85,350 shares during the period. Weaver Consulting Group raised its holdings in shares of Veru by 41.0% during the fourth quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock valued at $45,000 after acquiring an additional 20,280 shares during the period. PVG Asset Management Corp lifted its holdings in shares of Veru by 13.1% in the third quarter. PVG Asset Management Corp now owns 636,970 shares of the company’s stock valued at $490,000 after purchasing an additional 73,815 shares in the last quarter. Finally, Barclays PLC lifted its stake in Veru by 309.2% in the 3rd quarter. Barclays PLC now owns 184,777 shares of the company’s stock worth $142,000 after acquiring an additional 139,617 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Veru in a research note on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.